Capturing daily fluctuations in mood and cognition can help to more accurately monitor treatment response - but is this feasible for patients with depression?
In research presented at CNS2020, we examined the feasibility of high-frequency cognitive assessments, and their relationship with daily measures of depressive symptoms and physical activity.
The FDA have released guidance urging clinical trials to go virtual where possible in response to the COVID-19 pandemic – so what are the best methods for ensuring patient safety and trial integrity during this transition? In this article, we will discuss some of the important aspects to consider when taking a therapeutic trial from the clinic to the patient’s home.
The full FDA Guidance on Conduct of Clinical Trials of Medical Products During the COVID-19 Pandemic is available here.